



Governing Council Sixty-fifth Session

GC/65/12 Rev.1 8 May 2023

Lyon, 10–12 May 2023 Nouveau Centre Auditorium

APPOINTMENT OF NEW MEMBERS OF THE SCIENTIFIC COUNCIL - REVISION 1

- 1. In accordance with Article VI of the Statute and Resolution GC/61/R14, the term of office of 10 members of the Scientific Council, namely Drs Karima Bendahhou (Morocco), Tone Bjørge (Norway), Gunilla Enblad (Sweden), William Gallagher (Ireland), Ulrike Haug (Germany), Sergey Ivanov (Russian Federation), Ravi Mehrotra (India), Péter Nagy (Hungary), Jong Bae Park (Republic of Korea) and Pietro Pichierri (Italy) will be completed with the 2023 meeting of the Governing Council.
- 2. For the information of the Council, this leaves the following 16 members (8 women and 8 men) still serving on the Scientific Council: Drs Marc Arbyn (Belgium), Ferrán Catalá-López (Spain), Kalipso Chalkidou (UK), Louisa Gordon (Australia) and Manami Inoue (Japan) until 2024; Drs Einas Abdulaziz Eid Al Kuwari (Qatar), Walter Berger (Austria), Jie He (China), Marie-Elise Parent (Canada), Luis Felipe Ribeiro Pinto (Brazil) and Mathilde Touvier (France) until 2025; and Drs Jeanette Falck Winther (Denmark), Satish Gopal (USA), Sirpa Heinävaara (Finland), Valery Lemmens (Netherlands) and Ben Spycher (Switzerland) until 2026.
- 3. The areas of expertise of those members remaining on the Scientific Council are provided below for consideration by the Governing Council in making its selection of new Scientific Council members from among the nominations.

Name	Country	Term of office	Gender	Field of expertise
Marc Arbyn	Belgium	2021 – 2024	М	Obstetrics, gynecology, human papillomavirus, cancer screening and control, policy development, health-economic modelling
Ferrán Catalá López	Spain	2021 – 2024	М	Cancer epidemiology, public health, health economics
Kalipso Chalkidou	UK	2021 – 2024	F	Global health policy, health technology, healthcare coverage, epidemiology
Louisa Gordon	Australia	2021 – 2024	F	Health economics, early detection, cancer intervention, decision-analytic modelling
Manami Inoue	Japan	2021 – 2024	F	Cancer epidemiology, cancer registry methodology
Einas Abdulaziz Eid Al Kuwari	Qatar	2022 – 2025	F	Pathology and laboratory medicine

Name	Country	Term of office	Gender	Field of expertise
Walter Berger	Austria	2022 – 2025	M	Systemic cancer therapy with a focus on primary brain tumours, thoracic malignancies and sarcomas 1) Identification of novel therapeutic molecular targets and the respective inhibitors 2) Development of tumour-targeted small molecule anticancer agents 3) Dissection of drug resistance mechanisms and development of circumvention approaches
Jie He	China	2022 – 2025	M	Thoracic cancer surgery, translational research of thoracic cancers
Marie-Elise Parent	Canada	2022 – 2025	F	Cancer epidemiology, with a focus on the etiological role of occupational, environmental and lifestyle factors
Luis Felipe Ribeiro Pinto	Brazil	2022 – 2025	M	Mechanisms of carcinogenesis; molecular epidemiology; epigenetics and somatic mutations in relation to etiological factors; developing biomarkers of early detection or targeted therapies in upper aerodigestive tract tumours
Mathilde Touvier	France	2022 – 2025	F	Epidemiology; nutrition and cancer
Jeanette Falck Winther	DK	2023 – 2026	F	Cancer treatment in survivors of childhood cancer; molecular/genetic profiles; radiation; familial cancer syndromes (neurofibromatosis type 1) affecting children.
Satish Gopal	USA	2023 – 2026	М	Lymphoid malignancies; HIV-associated malignancies; low- and middle-income countries; clinical/translational research; cancer epidemiology; outcomes research.
Sirpa Heinävaara	Finland	2023 – 2026	F	Statistics, modelling systems, cancer mortality, screening strategies, radiation epidemiology.
Valery Lemmens	NL	2023 – 2026	M	Cancer epidemiology; Cancer registration; Public health; Implementation science; Social inequalities; Global statistics.
Ben Spycher	Switzerland	2023 – 2026	M	Biostatistics, epidemiology, childhood cancer, environmental exposures.

4. In accordance with Article VI.2 of the Agency's Statute, the Governing Council is requested to select new members to be appointed to the Scientific Council from the attached list of experts, one each from Germany, Hungary, India, Ireland, Italy, Morocco, Norway, the Republic of Korea, the Russian Federation and Sweden.

GERMANY

Professor André Karch Institute of Epidemiology and Social Medicine, University of Münster, Münster

Field: Causal inference in observational research, mammography screening, breast cancer, clinical epidemiology, biomarkers, statistical and epidemiological methods.

HUNGARY

Dr István Kenessey Head of Center, National Cancer Registry Budapest

Field: Epidemiology of cancer, cancer survivorship and the effect of advanced oncological therapies.

INDIA

Dr Prashant Mathur

National Centre for Disease Informatics and Research Indian Council of Medical Research (Department of Health Research, Ministry of Health and Family Welfare, Govt. of India), Bengaluru

Field: Noncommunicable diseases, epidemiology and surveillance (including cancer), cancer registrations, cancer risk reduction strategies.

Dr Shalini Singh ICMR-National Institute of Cancer Prevention and Research, Uttar Pradesh

Field: Cancer prevention, translation of molecular and metabolic pathways in cancer from bench to bedside, tobacco control research, capacity building for early detection and management of preinvasive cancer, implementation Research for scaling up known interventions for cancer control, women's health, cancer epidemiology, public health.

IRELAND

Dr David Hughes

Conway Institute and faculty of the School of Biomolecular and Biomedical Sciences in University College Dublin (UCD), Dublin

Field: Nutritional, genetic, molecular, and microbial epidemiology of various cancer sites. Leads large prospective cohort studies in the European Prospective Investigation of Cancer and Nutrition (EPIC).

Professor Orla Sheils
Vice-Provost/Chief Academic Officer
Faculty of Health Sciences
Trinity College Dublin

Field: Molecular pathology; molecular diagnostic assays; translational research; virally driven cancers; cancer prevention, detection, diagnosis, and treatment.

ITALY

Dr Roberta De Angelis

Head of Unit, Unit of Cancer Epidemiology and Genetics, Department of Oncology and Molecular Medicine

Italian National Institute of Health (ISS), Rome

Field: Descriptive and analytical cancer epidemiology; cancer registries; biostatistics; statistical methods to derive cancer burden and outcome indicators from population-based data.

Dr Ann Zeuner Research Director, Department of Oncology and Molecular Medicine Italian National Institute of Health (ISS), Rome

Field: Precision medicine (organoid technology, liquid biopsy, personalized anticancer therapies); molecular oncology; cancer immunology; identification of new therapeutic targets and mechanisms of therapy resistance; preclinical evaluation of novel antitumor agents; cancer stem cells; lung, breast and colorectal cancer.

MOROCCO

Dr Mohamed Berraho Faculté de Médecine, de Médecine Dentaire et de Pharmacie, Fès

Field: Cancer Epidemiology, epidemiology of cervical cancer, epidemiology of noncommunicable diseases (diabetes and hypertension), Epidemiology of NCD risk factors, mental health, occupational health.

NORWAY

Professor Pål Richard Romundstad Norwegian University of Science and Technology (NTNU), Trondheim

Field: Cancer epidemiology, reproductive epidemiology, mendelian randomization, life course and intergenerational studies.

REPUBLIC OF KOREA

Professor Young-Woo Kim Director of Research Institute of National Cancer Center, Goyang-si Gyeonggi-do

Field: Surgical oncology (gastric cancer); translational research (proteogenomics and drug development); medical engineering for surgical device development and patient blood management.

RUSSIAN FEDERATION

Dr Larisa Vladimirovna Bolotina
Moscow Oncology Research Institute named after
P. Hertsen – branch of Federal State Budgetary
Institution "National Medical Research
Radiological Centre", Ministry of Health,

Field: Drug therapy of tumours; modern methods of diagnosis, treatment and medical rehabilitation of patients with solid malignant tumours.

Dr Valeriy V. Breder

Moscow

Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology", Ministry of Health, Moscow

Field: Liver cancer: screening, early diagnosis, cancer treatment.

Lung cancer: chemotherapy, immunotherapy, targeted therapy.

SWEDEN

Professor David Gisselsson Nord Lund University, Division of Clinical Genetics, Department of Laboratory Medicine, Lund

Field: Genomics, childhood cancer, implementation of precision medicine, computational carcinogenesis, laboratory establishment in low-income countries.

Professor Anna Karlsson
Department of Laboratory Medicine (LABMED)
Karolinska Institutet, Stockholm

Field: Nucleotide metabolism with a focus on the treatment of viral diseases and cancer. Basic cell biology and biochemistry regarding mitochondrial DNA synthesis and function. Special focus to detect biomarkers for early detection of cancer and precision medicine, applying alterations of tumour cell metabolism. Experimental models.

NB: The *curricula vitae* will be distributed to Governing Council members only.